STOCKSGilead Buying Vertex Among Bold Biotech Stock Predictions for 2015By David SobekJan 9, 2015 10:42 AM EST
STOCKS2014 Healthcare Stock Report Card: Sobek Tracks His Hits and MissesBy David SobekDec 18, 2014 9:35 AM EST
STOCKSFoundation Medicine Winning Increased Insurance Coverage for Genetic Cancer TestsBy David SobekNov 19, 2014 11:17 AM EST
STOCKSStrong Prostate Cancer Drug Sales Will Help Medivation Expand PipelineBy David SobekNov 5, 2014 8:00 AM EST
STOCKSStock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental StrengthsBy David SobekOct 15, 2014 9:35 AM EDT
STOCKSAcceleron Hit Over Competitive Concerns, but Investors Overlook Rest of PipelineBy David SobekOct 2, 2014 9:21 AM EDT
STOCKSSafety Worries Over Celgene's Experimental Crohn's Drug OverblownBy David SobekSep 17, 2014 8:26 AM EDT
STOCKSTrade Ebola Stocks? Sure, But Don't Bet on Big Business OpportunityBy David SobekSep 10, 2014 9:36 AM EDT
STOCKSSeattle Genetics Nearing Key Test for Investor ConfidenceBy David SobekJul 16, 2014 9:03 AM EDT
STOCKSIncyte's Jakafi Unlikely to Benefit Pancreatic Cancer PatientsBy David SobekJun 11, 2014 9:50 AM EDT
STOCKSASCO '14: Foundation Medicine Builds Case for Insurance CoverageBy David SobekJun 2, 2014 7:45 AM EDT
STOCKSBull Thesis on Foundation Medicine: Using Big Data to Improve Treatment Decisions for Cancer PatientsBy David SobekMay 28, 2014 8:08 PM EDT
STOCKSMerrimack Pharma and the Marginal Benefit of Pancreatic Cancer Drug MM-398By David SobekMay 14, 2014 7:00 AM EDT
STOCKSFear Not, Biotech Stock 'Correction' Is Not a Bursting BubbleBy David SobekMay 7, 2014 10:18 AM EDT
STOCKSAnacor Pharma Remains Over-Valued on Development of Inferior DrugsBy David SobekApr 16, 2014 8:00 AM EDT
STOCKSConatus Pharma Deserves a Look by Investors in Love With Liver Disease StocksBy David SobekApr 9, 2014 10:06 AM EDT
STOCKSOnconova's MDS Study Fails and I Explain What I Got Wrong.By David SobekFeb 20, 2014 7:30 AM EST
STOCKSCempra Antibiotic Candidate Clears Important Heart Safety HurdleBy David SobekFeb 11, 2014 11:29 AM EST
STOCKSCancer Immunotherapy Combos: The Future Despite Fuzzy Road MapBy David SobekJan 30, 2014 12:06 PM EST
STOCKSThe State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and AcceleronBy David SobekJan 23, 2014 8:00 AM EST
STOCKSThe French Cancer Immunotherapy Stock Investors Don't Know, But Really ShouldBy David SobekJan 8, 2014 8:00 AM EST
STOCKSBiotech Stock Predictions 2014: Vertex is Bought, Alexion Sinks, BlueBird Flies And MoreBy David SobekDec 4, 2013 11:35 AM EST
STOCKSOnconova Weakness Improves Risk-Reward Heading Into Pivotal Study ResultsBy David SobekNov 19, 2013 8:08 AM EST
STOCKSCelgene's Revlimid Makes Stronger Case for European Front-Line ApprovalBy David SobekNov 13, 2013 10:38 AM EST
STOCKSOdds Favor Endocyte Receiving European Approval For Ovarian Cancer DrugBy David SobekOct 30, 2013 11:26 AM EDT
STOCKS3 Antibiotic Stocks Targeting Most Urgent Bacterial ThreatsBy David SobekOct 16, 2013 7:00 AM EDT
STOCKSBiotech Stock Bubble Talk Deflated By Cost-Conscious BuyersBy David SobekOct 2, 2013 8:30 AM EDT
STOCKSMerck Hopes Alzheimer's Drug Fares Better Than CompetitorsBy David SobekSep 5, 2013 8:00 AM EDT
STOCKSAlimera, pSivida Eye Drug Warrants FDA Approval On Third TryBy David SobekAug 28, 2013 9:30 AM EDT
STOCKSTetraphase: Another Good Investment In Hot Antibiotic MarketBy David SobekAug 7, 2013 10:14 AM EDT
